For therapeutic use in humans, the anti-sclerostin antibody (romosozumab) has been developed for the treatment of osteoporosis, which decreases endogenous levels of sclerostin, allowing for osteogenesis through an improvement in osteoblast survival [117,118,119]. The gene discussed is SOST; the disease is osteoporosis.